Stay updated on Y90-Radioembolization Plus Nivolumab in Asian HCC Clinical Trial
Sign up to get notified when there's something new on the Y90-Radioembolization Plus Nivolumab in Asian HCC Clinical Trial page.

Latest updates to the Y90-Radioembolization Plus Nivolumab in Asian HCC Clinical Trial page
- Check3 days agoChange DetectedThe page revision is updated from v3.0.1 to v3.0.2, signaling an update; the Back to Top element was removed.SummaryDifference0.2%
- Check10 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes in core content, names, pricing, or availability.SummaryDifference0.2%
- Check18 days agoChange DetectedThe web page has undergone significant updates, including the addition of new facility names and various types of proteins and antibodies, while removing several terms related to antineoplastic agents and specific location details.SummaryDifference3%
- Check25 days agoNo Change Detected
- Check32 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.1%
- Check39 days agoChange DetectedThe web page has been updated from version v2.16.10 to v2.16.11, indicating a revision in the content.SummaryDifference0.1%
- Check46 days agoChange DetectedThe page has been updated to reflect a new version, v2.16.10, and the previous service alert regarding planned maintenance has been removed.SummaryDifference1%
Stay in the know with updates to Y90-Radioembolization Plus Nivolumab in Asian HCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Y90-Radioembolization Plus Nivolumab in Asian HCC Clinical Trial page.